John D. Dobak
Founder en JAKK Group, Inc. .
Fortuna: 490 482 $ al 31/03/2024
Relaciones activas
Nombre | Sexo | Edad | Empresas relacionadas | Colaboración |
---|---|---|---|---|
Cynthia Collins | F | 65 |
DermTech Operations, Inc.
DermTech Operations, Inc. Medical SpecialtiesHealth Technology DermTech Operations, Inc. engages in the provision of molecular dermatology. It develops products that facilitate the early detection of skin cancers, assess inflammatory diseases, and customize drug treatments. The firm's products include adhesive skin collection kit, pigmented lesion assay (PLA), nevome, inflammatory disease and carcinome. The company was founded by Lawrence A. Rheins in 1996 and is headquartered in La Jolla, CA. | 6 años |
Burkhard Jansen | M | 58 |
DermTech Operations, Inc.
DermTech Operations, Inc. Medical SpecialtiesHealth Technology DermTech Operations, Inc. engages in the provision of molecular dermatology. It develops products that facilitate the early detection of skin cancers, assess inflammatory diseases, and customize drug treatments. The firm's products include adhesive skin collection kit, pigmented lesion assay (PLA), nevome, inflammatory disease and carcinome. The company was founded by Lawrence A. Rheins in 1996 and is headquartered in La Jolla, CA. | 11 años |
Bret Christensen | M | 53 | 1 años | |
Kirk Malloy | M | 57 | 2 años | |
Mark Capone | M | 61 | 2 años | |
Ray Akhavan | M | 55 | 3 años | |
Nathalie Keraudy | F | 45 | 3 años | |
Bret W. Jorgensen | M | 65 |
San Diego YPO, Inc.
| - |
James Rock | M | 55 | 5 años | |
Rachel Williams | F | - | 4 años | |
Loren Clarke | M | - | 3 años | |
Jennifer Eilemberg | F | - | 2 años | |
Steven Stone | M | - | 2 años |
Gráfico relacional
Relaciones con varias empresas
Antiguas relaciones
Nombre | Sexo | Edad | Empresas relacionadas | Colaboración |
---|---|---|---|---|
Gary Jacobs | M | 67 |
DermTech Operations, Inc.
DermTech Operations, Inc. Medical SpecialtiesHealth Technology DermTech Operations, Inc. engages in the provision of molecular dermatology. It develops products that facilitate the early detection of skin cancers, assess inflammatory diseases, and customize drug treatments. The firm's products include adhesive skin collection kit, pigmented lesion assay (PLA), nevome, inflammatory disease and carcinome. The company was founded by Lawrence A. Rheins in 1996 and is headquartered in La Jolla, CA. | 15 años |
George W. Mahaffey | M | 65 |
Neothetics, Inc.
Neothetics, Inc. Pharmaceuticals: MajorHealth Technology Neothetics, Inc. operates as a holding company, which provides clinical-stage specialty pharmaceutical and developing therapeutics for the aesthetic. It focuses on localized fat reduction and body contouring. The company products include LIPO-202, is an injectable formulation of the long-acting ß2-adrenergic receptor agonist, salmeterol xinafoate. Neothetics was founded by John D. Dobak in February 2007 and is headquartered in San Diego, CA. | 5 años |
Scott R. Pancoast | M | 58 |
DermTech Operations, Inc.
DermTech Operations, Inc. Medical SpecialtiesHealth Technology DermTech Operations, Inc. engages in the provision of molecular dermatology. It develops products that facilitate the early detection of skin cancers, assess inflammatory diseases, and customize drug treatments. The firm's products include adhesive skin collection kit, pigmented lesion assay (PLA), nevome, inflammatory disease and carcinome. The company was founded by Lawrence A. Rheins in 1996 and is headquartered in La Jolla, CA. | 9 años |
Sarah Dion | F | - | 4 años | |
Maria Feldman | F | - |
Neothetics, Inc.
Neothetics, Inc. Pharmaceuticals: MajorHealth Technology Neothetics, Inc. operates as a holding company, which provides clinical-stage specialty pharmaceutical and developing therapeutics for the aesthetic. It focuses on localized fat reduction and body contouring. The company products include LIPO-202, is an injectable formulation of the long-acting ß2-adrenergic receptor agonist, salmeterol xinafoate. Neothetics was founded by John D. Dobak in February 2007 and is headquartered in San Diego, CA. | - |
Steven J. Kemper | M | 69 | - | |
Zu Xu Yao | M | - |
DermTech Operations, Inc.
DermTech Operations, Inc. Medical SpecialtiesHealth Technology DermTech Operations, Inc. engages in the provision of molecular dermatology. It develops products that facilitate the early detection of skin cancers, assess inflammatory diseases, and customize drug treatments. The firm's products include adhesive skin collection kit, pigmented lesion assay (PLA), nevome, inflammatory disease and carcinome. The company was founded by Lawrence A. Rheins in 1996 and is headquartered in La Jolla, CA. | 2 años |
Todd Wood | M | 55 |
DermTech Operations, Inc.
DermTech Operations, Inc. Medical SpecialtiesHealth Technology DermTech Operations, Inc. engages in the provision of molecular dermatology. It develops products that facilitate the early detection of skin cancers, assess inflammatory diseases, and customize drug treatments. The firm's products include adhesive skin collection kit, pigmented lesion assay (PLA), nevome, inflammatory disease and carcinome. The company was founded by Lawrence A. Rheins in 1996 and is headquartered in La Jolla, CA. | 4 años |
Maxim Gorbachev | M | 48 |
Neothetics, Inc.
Neothetics, Inc. Pharmaceuticals: MajorHealth Technology Neothetics, Inc. operates as a holding company, which provides clinical-stage specialty pharmaceutical and developing therapeutics for the aesthetic. It focuses on localized fat reduction and body contouring. The company products include LIPO-202, is an injectable formulation of the long-acting ß2-adrenergic receptor agonist, salmeterol xinafoate. Neothetics was founded by John D. Dobak in February 2007 and is headquartered in San Diego, CA. | - |
Gene Salkind | M | 71 |
DermTech Operations, Inc.
DermTech Operations, Inc. Medical SpecialtiesHealth Technology DermTech Operations, Inc. engages in the provision of molecular dermatology. It develops products that facilitate the early detection of skin cancers, assess inflammatory diseases, and customize drug treatments. The firm's products include adhesive skin collection kit, pigmented lesion assay (PLA), nevome, inflammatory disease and carcinome. The company was founded by Lawrence A. Rheins in 1996 and is headquartered in La Jolla, CA. | 16 años |
Daniel Janney | M | 58 |
Neothetics, Inc.
Neothetics, Inc. Pharmaceuticals: MajorHealth Technology Neothetics, Inc. operates as a holding company, which provides clinical-stage specialty pharmaceutical and developing therapeutics for the aesthetic. It focuses on localized fat reduction and body contouring. The company products include LIPO-202, is an injectable formulation of the long-acting ß2-adrenergic receptor agonist, salmeterol xinafoate. Neothetics was founded by John D. Dobak in February 2007 and is headquartered in San Diego, CA. | 8 años |
Karen E. Peterson | F | 66 |
Leptos Biomedical, Inc.
Leptos Biomedical, Inc. Medical SpecialtiesHealth Technology Leptos is developing a proprietary neuromodulation therapy for chronic obesity. The treatment, delivered via a pacemaker-type device, involves electrical activation of a specific nerve in the autonomic nervous system. They believe that this therapy may offer an effective minimally invasive, reversible surgical option for people suffering from chronic obesity. As yet, the Leptos therapy is not approved for sale in the United States and is limited to investigational use. | 4 años |
Susan Knudson | F | 60 |
Neothetics, Inc.
Neothetics, Inc. Pharmaceuticals: MajorHealth Technology Neothetics, Inc. operates as a holding company, which provides clinical-stage specialty pharmaceutical and developing therapeutics for the aesthetic. It focuses on localized fat reduction and body contouring. The company products include LIPO-202, is an injectable formulation of the long-acting ß2-adrenergic receptor agonist, salmeterol xinafoate. Neothetics was founded by John D. Dobak in February 2007 and is headquartered in San Diego, CA. | 8 años |
Monica Tellado | F | 51 | 2 años | |
Martha Demski | F | 71 |
Neothetics, Inc.
Neothetics, Inc. Pharmaceuticals: MajorHealth Technology Neothetics, Inc. operates as a holding company, which provides clinical-stage specialty pharmaceutical and developing therapeutics for the aesthetic. It focuses on localized fat reduction and body contouring. The company products include LIPO-202, is an injectable formulation of the long-acting ß2-adrenergic receptor agonist, salmeterol xinafoate. Neothetics was founded by John D. Dobak in February 2007 and is headquartered in San Diego, CA. | 4 años |
Kim Kamdar | M | 56 |
Neothetics, Inc.
Neothetics, Inc. Pharmaceuticals: MajorHealth Technology Neothetics, Inc. operates as a holding company, which provides clinical-stage specialty pharmaceutical and developing therapeutics for the aesthetic. It focuses on localized fat reduction and body contouring. The company products include LIPO-202, is an injectable formulation of the long-acting ß2-adrenergic receptor agonist, salmeterol xinafoate. Neothetics was founded by John D. Dobak in February 2007 and is headquartered in San Diego, CA. | - |
Matthew Posard | M | 56 |
DermTech Operations, Inc.
DermTech Operations, Inc. Medical SpecialtiesHealth Technology DermTech Operations, Inc. engages in the provision of molecular dermatology. It develops products that facilitate the early detection of skin cancers, assess inflammatory diseases, and customize drug treatments. The firm's products include adhesive skin collection kit, pigmented lesion assay (PLA), nevome, inflammatory disease and carcinome. The company was founded by Lawrence A. Rheins in 1996 and is headquartered in La Jolla, CA. | - |
Kevin G. Connors | M | - |
Leptos Biomedical, Inc.
Leptos Biomedical, Inc. Medical SpecialtiesHealth Technology Leptos is developing a proprietary neuromodulation therapy for chronic obesity. The treatment, delivered via a pacemaker-type device, involves electrical activation of a specific nerve in the autonomic nervous system. They believe that this therapy may offer an effective minimally invasive, reversible surgical option for people suffering from chronic obesity. As yet, the Leptos therapy is not approved for sale in the United States and is limited to investigational use. | - |
Michael Willis | M | 60 |
DermTech Operations, Inc.
DermTech Operations, Inc. Medical SpecialtiesHealth Technology DermTech Operations, Inc. engages in the provision of molecular dermatology. It develops products that facilitate the early detection of skin cancers, assess inflammatory diseases, and customize drug treatments. The firm's products include adhesive skin collection kit, pigmented lesion assay (PLA), nevome, inflammatory disease and carcinome. The company was founded by Lawrence A. Rheins in 1996 and is headquartered in La Jolla, CA. | - |
Patrick Johnson | M | - | 2 años | |
Ray Bassi | M | - | 2 años | |
Zuxu Yao | M | 60 | 9 años | |
Michael Howell | M | 47 | 2 años | |
Lincoln Krochmal | M | 78 |
Neothetics, Inc.
Neothetics, Inc. Pharmaceuticals: MajorHealth Technology Neothetics, Inc. operates as a holding company, which provides clinical-stage specialty pharmaceutical and developing therapeutics for the aesthetic. It focuses on localized fat reduction and body contouring. The company products include LIPO-202, is an injectable formulation of the long-acting ß2-adrenergic receptor agonist, salmeterol xinafoate. Neothetics was founded by John D. Dobak in February 2007 and is headquartered in San Diego, CA. | 3 años |
Steve Salmon | M | 63 |
Leptos Biomedical, Inc.
Leptos Biomedical, Inc. Medical SpecialtiesHealth Technology Leptos is developing a proprietary neuromodulation therapy for chronic obesity. The treatment, delivered via a pacemaker-type device, involves electrical activation of a specific nerve in the autonomic nervous system. They believe that this therapy may offer an effective minimally invasive, reversible surgical option for people suffering from chronic obesity. As yet, the Leptos therapy is not approved for sale in the United States and is limited to investigational use. | - |
Chris Kemmerer | M | 60 |
Neothetics, Inc.
Neothetics, Inc. Pharmaceuticals: MajorHealth Technology Neothetics, Inc. operates as a holding company, which provides clinical-stage specialty pharmaceutical and developing therapeutics for the aesthetic. It focuses on localized fat reduction and body contouring. The company products include LIPO-202, is an injectable formulation of the long-acting ß2-adrenergic receptor agonist, salmeterol xinafoate. Neothetics was founded by John D. Dobak in February 2007 and is headquartered in San Diego, CA. | 8 años |
Kevin Sun | M | 46 |
DermTech Operations, Inc.
DermTech Operations, Inc. Medical SpecialtiesHealth Technology DermTech Operations, Inc. engages in the provision of molecular dermatology. It develops products that facilitate the early detection of skin cancers, assess inflammatory diseases, and customize drug treatments. The firm's products include adhesive skin collection kit, pigmented lesion assay (PLA), nevome, inflammatory disease and carcinome. The company was founded by Lawrence A. Rheins in 1996 and is headquartered in La Jolla, CA. | - |
John F. Wood | M | - |
Neothetics, Inc.
Neothetics, Inc. Pharmaceuticals: MajorHealth Technology Neothetics, Inc. operates as a holding company, which provides clinical-stage specialty pharmaceutical and developing therapeutics for the aesthetic. It focuses on localized fat reduction and body contouring. The company products include LIPO-202, is an injectable formulation of the long-acting ß2-adrenergic receptor agonist, salmeterol xinafoate. Neothetics was founded by John D. Dobak in February 2007 and is headquartered in San Diego, CA. | - |
Darryl Garrison | M | - | - | |
Claudia Ibarra | F | 61 | 5 años | |
Tyler van Buren | M | - |
Neothetics, Inc.
Neothetics, Inc. Pharmaceuticals: MajorHealth Technology Neothetics, Inc. operates as a holding company, which provides clinical-stage specialty pharmaceutical and developing therapeutics for the aesthetic. It focuses on localized fat reduction and body contouring. The company products include LIPO-202, is an injectable formulation of the long-acting ß2-adrenergic receptor agonist, salmeterol xinafoate. Neothetics was founded by John D. Dobak in February 2007 and is headquartered in San Diego, CA. | 2 años |
Karen M. Boezi | F | - |
Leptos Biomedical, Inc.
Leptos Biomedical, Inc. Medical SpecialtiesHealth Technology Leptos is developing a proprietary neuromodulation therapy for chronic obesity. The treatment, delivered via a pacemaker-type device, involves electrical activation of a specific nerve in the autonomic nervous system. They believe that this therapy may offer an effective minimally invasive, reversible surgical option for people suffering from chronic obesity. As yet, the Leptos therapy is not approved for sale in the United States and is limited to investigational use. | - |
Ralph Peter Cardinal | M | 59 |
Leptos Biomedical, Inc.
Leptos Biomedical, Inc. Medical SpecialtiesHealth Technology Leptos is developing a proprietary neuromodulation therapy for chronic obesity. The treatment, delivered via a pacemaker-type device, involves electrical activation of a specific nerve in the autonomic nervous system. They believe that this therapy may offer an effective minimally invasive, reversible surgical option for people suffering from chronic obesity. As yet, the Leptos therapy is not approved for sale in the United States and is limited to investigational use. | 3 años |
Thomas Wiggans | M | 72 |
Neothetics, Inc.
Neothetics, Inc. Pharmaceuticals: MajorHealth Technology Neothetics, Inc. operates as a holding company, which provides clinical-stage specialty pharmaceutical and developing therapeutics for the aesthetic. It focuses on localized fat reduction and body contouring. The company products include LIPO-202, is an injectable formulation of the long-acting ß2-adrenergic receptor agonist, salmeterol xinafoate. Neothetics was founded by John D. Dobak in February 2007 and is headquartered in San Diego, CA. | 3 años |
Kobi Iki | M | - |
Leptos Biomedical, Inc.
Leptos Biomedical, Inc. Medical SpecialtiesHealth Technology Leptos is developing a proprietary neuromodulation therapy for chronic obesity. The treatment, delivered via a pacemaker-type device, involves electrical activation of a specific nerve in the autonomic nervous system. They believe that this therapy may offer an effective minimally invasive, reversible surgical option for people suffering from chronic obesity. As yet, the Leptos therapy is not approved for sale in the United States and is limited to investigational use. | - |
Enrico Picozza | M | 64 | 3 años | |
Herm Rosenman | M | 76 |
DermTech Operations, Inc.
DermTech Operations, Inc. Medical SpecialtiesHealth Technology DermTech Operations, Inc. engages in the provision of molecular dermatology. It develops products that facilitate the early detection of skin cancers, assess inflammatory diseases, and customize drug treatments. The firm's products include adhesive skin collection kit, pigmented lesion assay (PLA), nevome, inflammatory disease and carcinome. The company was founded by Lawrence A. Rheins in 1996 and is headquartered in La Jolla, CA. | 2 años |
Frank Fischer | M | 82 |
Leptos Biomedical, Inc.
Leptos Biomedical, Inc. Medical SpecialtiesHealth Technology Leptos is developing a proprietary neuromodulation therapy for chronic obesity. The treatment, delivered via a pacemaker-type device, involves electrical activation of a specific nerve in the autonomic nervous system. They believe that this therapy may offer an effective minimally invasive, reversible surgical option for people suffering from chronic obesity. As yet, the Leptos therapy is not approved for sale in the United States and is limited to investigational use. | - |
Kenneth W. Locke | M | 67 |
Neothetics, Inc.
Neothetics, Inc. Pharmaceuticals: MajorHealth Technology Neothetics, Inc. operates as a holding company, which provides clinical-stage specialty pharmaceutical and developing therapeutics for the aesthetic. It focuses on localized fat reduction and body contouring. The company products include LIPO-202, is an injectable formulation of the long-acting ß2-adrenergic receptor agonist, salmeterol xinafoate. Neothetics was founded by John D. Dobak in February 2007 and is headquartered in San Diego, CA. | 8 años |
James Walter Glasheen | M | 56 |
Leptos Biomedical, Inc.
Leptos Biomedical, Inc. Medical SpecialtiesHealth Technology Leptos is developing a proprietary neuromodulation therapy for chronic obesity. The treatment, delivered via a pacemaker-type device, involves electrical activation of a specific nerve in the autonomic nervous system. They believe that this therapy may offer an effective minimally invasive, reversible surgical option for people suffering from chronic obesity. As yet, the Leptos therapy is not approved for sale in the United States and is limited to investigational use. | - |
Murray C. Maytom | M | - |
Neothetics, Inc.
Neothetics, Inc. Pharmaceuticals: MajorHealth Technology Neothetics, Inc. operates as a holding company, which provides clinical-stage specialty pharmaceutical and developing therapeutics for the aesthetic. It focuses on localized fat reduction and body contouring. The company products include LIPO-202, is an injectable formulation of the long-acting ß2-adrenergic receptor agonist, salmeterol xinafoate. Neothetics was founded by John D. Dobak in February 2007 and is headquartered in San Diego, CA. | - |
Estadísticas
País | Relaciones | % del total |
---|---|---|
Estados Unidos | 54 | 100.00% |
Antigüedad de la relación
Activas
Pasados
Hombre
Mujer
Administradores
Ejecutivos
Origen de las relaciones
- Bolsa de valores
- Insiders
- John D. Dobak
- Red Personal